Literature DB >> 23920127

Immune microenvironment profiles of tumor immune equilibrium and immune escape states of mouse sarcoma.

Xi Wu1, Meiyu Peng, Bingqing Huang, Huan Zhang, Huafeng Wang, Biao Huang, Zhenyi Xue, Lijuan Zhang, Yurong Da, De Yang, Zhi Yao, Rongxin Zhang.   

Abstract

Cancer immunoediting consists of three distinct phases: elimination, equilibrium and escape. Here, for the first time, we investigated the immune microenvironment profiles of tumor immune equilibrium and immune escape states in 3'-methylcholanthrene-induced murine sarcoma model. Our study indicates the relative balance of monocytic MDSCs and antitumor immunity cells (especially CTLs, NK cells and γδT cells) may involve in maintaining tumor cells in a state of immune-mediated dormancy. In addition, high percentages of Treg cells and PMN-MDSCs are associated with the tumor immune escape state - mice with progressing sarcomas. In summary, the relative balance of immune effector cells and suppressive populations in the tumor microenvironment may involve in determining the fate of tumors.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Dormant sarcomas; Immune equilibrium; Immune escape; Immune microenvironment; Immunoediting

Mesh:

Substances:

Year:  2013        PMID: 23920127     DOI: 10.1016/j.canlet.2013.07.038

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  21 in total

1.  Astragaloside IV inhibits progression of lung cancer by mediating immune function of Tregs and CTLs by interfering with IDO.

Authors:  Anle Zhang; Yuanhong Zheng; Zujun Que; Lingling Zhang; Shengchao Lin; Vanminh Le; Jianwen Liu; Jianhui Tian
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-01       Impact factor: 4.553

2.  Identification of a highly immunogenic mouse breast cancer sub cell line, 4T1-S.

Authors:  Hirotake Abe; Haruka Wada; Muhammad Baghdadi; Sayaka Nakanishi; Yuu Usui; Takahiro Tsuchikawa; Toshiaki Shichinohe; Satoshi Hirano; Ken-Ichiro Seino
Journal:  Hum Cell       Date:  2016-02-08       Impact factor: 4.174

Review 3.  Targeting cancer-related inflammation in the era of immunotherapy.

Authors:  Kyohei Nakamura; Mark J Smyth
Journal:  Immunol Cell Biol       Date:  2017-01-10       Impact factor: 5.126

Review 4.  Cancer Immunoprevention: Current Status and Future Directions.

Authors:  Mahsa Keshavarz-Fathi; Nima Rezaei
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2021-02-27       Impact factor: 4.291

Review 5.  New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape.

Authors:  Deepak Mittal; Matthew M Gubin; Robert D Schreiber; Mark J Smyth
Journal:  Curr Opin Immunol       Date:  2014-02-14       Impact factor: 7.486

Review 6.  Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells.

Authors:  M Pizzi; M Boi; F Bertoni; G Inghirami
Journal:  Leukemia       Date:  2016-06-08       Impact factor: 11.528

7.  Effects of transarterial chemoembolization on the immunological function of patients with hepatocellular carcinoma.

Authors:  Jingjing Guo; Saixia Wang; Yujing Han; Zhongyuan Jia; Runchao Wang
Journal:  Oncol Lett       Date:  2021-05-24       Impact factor: 2.967

Review 8.  Myeloid derived suppressor cells and the release of micro-metastases from dormancy.

Authors:  Saraswoti Khadge; Kathryn Cole; James E Talmadge
Journal:  Clin Exp Metastasis       Date:  2021-05-20       Impact factor: 4.510

Review 9.  Cancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant State.

Authors:  Constantin N Baxevanis; Sonia A Perez
Journal:  Vaccines (Basel)       Date:  2015-07-30

10.  Tumor dormancy: potential therapeutic target in tumor recurrence and metastasis prevention.

Authors:  Sih-Han Wang; Shiaw-Yih Lin
Journal:  Exp Hematol Oncol       Date:  2013-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.